- Guide to PHARMACOLOGY
Synonyms: CC90005 | compound 57 [PMID: 34355886]
Compound class: Synthetic organic
Comment: CC-90005 is reported as an orally active selective protein kinase C theta (PCKθ) inhibitor . It was developed by Celgene (Bristol Myers Squibb) for potential to inhibit TCR-mediated T cell activation, proliferation, and cytokine production, as an anti-inflammatory modality for the treatment of T cell-driven autoimmune diseases . CC-90005 induces T cell anergy. It is >550-fold selective for PCKθ compared to PCKδ.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Papa P, Whitefield B, Mortensen DS, Cashion D, Huang D, Torres E, Parnes J, Sapienza J, Hansen J, Correa M et al.. (2021)
Discovery of the Selective Protein Kinase C-θ Kinase Inhibitor, CC-90005.
J Med Chem, 64 (16): 11886-11903. [PMID:34355886]
2. Zhang EY, Kong KF, Altman A. (2013)
The yin and yang of protein kinase C-theta (PKCθ): a novel drug target for selective immunosuppression.
Adv Pharmacol, 66: 267-312. [PMID:23433459]